Potassium Sorbate vs Propylene Glycol: which is worse?

What is Potassium Sorbate?

Potassium sorbate is the potassium salt of sorbic acid, a naturally occurring short-chain fatty acid originally derived from the mountain ash berry (Sorbus aucuparia). Commercial potassium sorbate is synthetically produced by reacting sorbic acid with potassium hydroxide. It is the most widely used food preservative globally.

What is Propylene Glycol?

Propylene glycol is a synthetic organic compound used as a humectant, solvent, and emulsifier in food, pharmaceuticals, cosmetics, and industrial applications. It is produced from propylene oxide (derived from petroleum). Its chemical formula is C3H8O2.

Documented risks

Potassium Sorbate: Potassium sorbate has a generally good safety profile compared to other synthetic preservatives. EFSA's 2015 re-evaluation maintained the ADI at 3 mg/kg body weight, finding no significant carcinogenicity or genotoxicity. However, some human and in vitro studies have documented concerns. A 2010 study in Toxicology in Vitro found potassium sorbate was genotoxic (caused DNA strand breaks) in human blood cells at concentrations achievable in food. The study found it damaged peripheral blood lymphocytes. A 2014 study in Food and Chemical Toxicology found potassium sorbate caused DNA damage in human lymphocytes at food use concentrations. Contact dermatitis and allergic reactions from topical use are documented. At very high doses in animal studies, liver and kidney effects have been observed. The general regulatory consensus is that potassium sorbate is one of the safer food preservatives, but the in vitro genotoxicity findings deserve attention.

Propylene Glycol: Propylene glycol is generally considered safe by the FDA and is metabolized by the liver to lactic acid and pyruvate (normal metabolites). However, at high doses — particularly from intravenous pharmaceutical formulations — propylene glycol can accumulate and cause lactic acidosis, kidney toxicity, and CNS effects. These effects are seen in critically ill patients receiving high-dose PG-containing intravenous medications, not from food consumption. In children and people with impaired liver or kidney function, PG accumulation may occur at lower doses than in healthy adults. Animal studies have found reproductive and developmental effects at high doses. EFSA's 2018 re-evaluation found no concerns at typical food use levels but noted the EU limits PG use as a direct food additive, using it only as a carrier solvent for permitted additives.